P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

Abstract

In crizotinib-refractory ROS1+ non small-cell lung cancer NSCLC, lorlatinib showed intracranial and systemic activity especially in absence of acquired ROS1 mutations. Other molecular events potentially affecting sensitivity to lorlatinib remain to be explored. In the prospective PFROST trial, which evaluated lorlatinib at crizotinib failure, response rate (RR) was >40%; median progression-free survival (PFS) and overall survival (OS) were 8.9 months and not reached, respectively. Here, we present final results of the trial focusing on the role of molecular events in modulating activity of lorlatinib.